PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report.
Manavi SachdevaNatalie Yan Li NgoiDiana LimMichelle L M PoonYee Liang ThianYi Wan LimSiew Eng LimPearl TongJeffrey H Y LumJoseph NgArunachalam IlancheranEfren J DomingoJeffrey J H LowDavid Shao Peng TanPublished in: OncoTargets and therapy (2021)
Pembrolizumab was active in this patient with chemotherapy-refractory VCCC which harbored high PD-L1 CPS. Further studies to determine the role of immune check-point blockade in the treatment of VCCC are warranted.